Why so defensive?I'm not the one calling for FX-322 to be "burned to the ground". It will play out however it plays out. Heck, even if Neuromod magically versions up Lenire to the point where it actually works unequivocally and eliminates risk of "disimprovement" I'll reconsider them as well.
You obviously haven't been paying attention to the thread--namely the part where someone tried to essentially banish me from it. That might make one defensive, don't you think? Anyway, I have to imagine most reading this thread do not want to read all of this member on member drama. It's all noise.Why so defensive?
Does PIPE-505 regenerate (create new hair cells) hair cells? Or does it cure damaged hair cells?I'm quite shocked that the age-related hearing loss trial wasn't successful.
If the severe hearing loss trial isn't successful as well, that means they will try and run the trial only for mild-moderately severe patients as previous trials with these patients were successful. I'm glad they are sticking with the single dose moving forward and finding out which patients will benefit from FX-322.
I'm hoping PIPE-505 results coming out this month are positive. Having PIPE-505 regrow synapses and some OHCs in addition to FX-322 regrowing IHCs and some OHCs should solve most of our problems such as hyperacusis, tinnitus and hearing loss.
If PIPE-505 goes into Phase 2 as soon as their Phase 1 results come out, we could be seeing a similar timeline with FX-322 where both drugs come out in the market at the same time.
I do wonder if the key to solving our issues is that we need both FX-322 and PIPE-505 injected.
It's not very clear, but PIPE-505 is believed to cause some support cells to differentiate into OHC. Thereby depleting the support cells. Somehow it also causes existing OHC to regenerate missing synapses.Does PIPE-505 regenerate (create new hair cells) hair cells? Or does it cure damaged hair cells?
FX-322 creates new hair cells.
If so, can these two drugs be divided into roles?
It seems to be the same "Forced Differentiation" as Audion Therapeutics. It looks like γ-secretase inhibitor. In terms of depletion of support cells, I think OTO-413 is better in combination with FX-322.It's not very clear, but PIPE-505 is believed to cause some support cells to differentiate into OHC. Thereby depleting the support cells. Somehow it also causes existing OHC to regenerate missing synapses.
Just to clarify, PIPE-505 would regenerate the Type 1 synapses which connect to the inner hair cells. The OHCs synapse onto Type 2s, which are not involved in synaptopathy.It's not very clear, but PIPE-505 is believed to cause some support cells to differentiate into OHC. Thereby depleting the support cells. Somehow it also causes existing OHC to regenerate missing synapses.
If successful, I could see it being used after FX-322 treatment. FX-322 would cause mitosis of the progenitor cells; creating new hair cells that synapse. PIPE-505 would then cause any existing hair cells that were functioning with missing synapses to synapse.
Thanks for clarifying.Just to clarify, PIPE-505 would regenerate the Type 1 synapses which connect to the inner hair cells. The OHCs synapse onto Type 2s, which are not involved in synaptopathy.
Could you show me where you found this?Just to clarify, PIPE-505 would regenerate the Type 1 synapses which connect to the inner hair cells. The OHCs synapse onto Type 2s, which are not involved in synaptopathy.
Could you show me where you found this?
Thanks.
I wonder if regrowing IHC Type 1 ribbon synapses will reduce OHC Type 2 ribbon synapses once you get PIPE-505 injected.https://www.pipelinetherapeutics.com/news/Society-for-Neuroscience-49th-Annual-Meeting-Chicago.pdf
It says right here that PIPE-505 leads to regeneration of inner hair cell ribbon synapses aka Type 1s. When people refer to synaptopathy, it refers to the these connections. These are the connections that have been implicated in hidden hearing loss and tinnitus/loudness hyperacusis, if lost. It has been established that the Type 2 ribbon synapses can in fact increase in number following acoustic trauma, whilst the Type 1s decrease - so essentially they have opposite reactions to acoustic trauma.
Acoustic Trauma Increases Ribbon Number and Size in Outer Hair Cells of the Mouse Cochlea
I have wondered this too although it's important to point out that there are a lot of unanswered questions - see this talk Megan Wood gave from 32:00 onwards where she addresses these. E.g it is not known whether this effect persists or not and how things like inflammation or cell death could affect OHC ribbons.I wonder if regrowing IHC Type 1 ribbon synapses will reduce OHC Type 2 ribbon synapses once you get PIPE-505 injected.
Is that how it works?I wonder if regrowing IHC Type 1 ribbon synapses will reduce OHC Type 2 ribbon synapses once you get PIPE-505 injected.
Hopefully we will have some answers soon in the upcoming years.I have wondered this too although it's important to point out that there are a lot of unanswered questions - see this talk Megan Wood gave from 32:00 onwards where she addresses these. E.g it is not known whether this effect persists or not and how things like inflammation or cell death could affect OHC ribbons.
The interim results only commented on primary outcomes so I expect we will see the results for tinnitus in the final readout.Did they ever release any data on how FX-322 affects tinnitus? I thought that was a secondary measure they were tracking.
Interesting stuff. It will be a while before it is known if cell regeneration / synaptogenesis in other areas of the cochlea leads to a reversed change in those cells / synapses that changed from noise damage. I would think in the case of OHC suspected to cause hyperacusis / pain, that more new OHC properly synapsed to the Type 2 nerve alongside damaged/"oversynapsed" may help at least dampen the effect of hyperacusis. Just a theory.I have wondered this too although it's important to point out that there are a lot of unanswered questions - see this talk Megan Wood gave from 32:00 onwards where she addresses these. E.g it is not known whether this effect persists or not and how things like inflammation or cell death could affect OHC ribbons.
Are we expecting any new data to be presented. Boy they have a lot of studies that should have data rolling in shortly.Gentle Reminder - Few hours to go for the Jefferies Virtual Healthcare Conference
https://investors.frequencytx.com/events/event-details/jefferies-virtual-healthcare-conference-0
The trials are scheduled to be completed this month. I expect good results. Otherwise if no results, they will only be putting out a press release...Are we expecting any new data to be presented. Boy they have a lot of studies that should have data rolling in shortly.
Also does anyone know off-hand (and I know that you do), are the 111,112, and 113 studies with a single injection?
Where are they saying that?Interesting that they are now saying, "Upcoming Phase 2 Trials" (plural) for FX-322.
1. On the Jefferies webcast just nowWhere are they saying that?